Latest news in cancer
T-cell therapy for gastric, liver and pancreatic cancer
May 2022: T-cell therapy has begun a vigorous attack on digestive system malignancies, and T-cell immunotherapy has triumphed over refractory tumours like...
FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumors
May 2022: FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumours in a CAR-NK clinical trial. The FDA...
Patient experience of CAR T-cell therapy suffering from acute lymphoblastic leukemia
May 2022: Matthew is a 27-year-old patient with Acute Lymphoblastic Leukemia who was diagnosed in 2015. Unfortunately, the standard treatment of chemotherapy...
CAR T-Cell therapy for mantle cell lymphoma (MCL)
Induction therapy followed by stem cell transplantation has maintained a role in the treatment of mantle cell lymphoma (MCL), according to James Gerson, MD,...
Fam-trastuzumab deruxtecan-nxki is approved by FDA for breast cancer
April 2022: Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the...
Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer
April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis...
Pembrolizumab is approved for advanced endometrial carcinoma
April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial...
First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma
April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of...
JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma
China’s National Medical Products Administration (NMPA) has approved JW Therapeutics’ investigational new drug (IND) application for a key clinical...
Can CAR T-Cell manufacturing time be reduced to just one day?
April 2022: Normally, the cell manufacturing procedure for CAR T-cell therapy takes nine to fourteen days; however, researchers at the University of...
CAR T-Cell therapy in solid tumors – A research study
March 2022: Blood vessels are supposed to behave like trees, pouring oxygen into tissues in order for them to flourish and immune cells to clean infections...
CAR T- cell therapy for breast cancer is on the cards
March 2022: According to researchers at the UNC Lineberger Comprehensive Cancer Center, adding a tiny chemical to a treatment process called chimeric antigen...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.